Insider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) COO Sells 4,578 Shares of Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) COO Alistair Milnes sold 4,578 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $64,504.02. Following the completion of the transaction, the chief operating officer now owns 100,724 shares of the company’s stock, valued at $1,419,201.16. This represents a 4.35 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock traded down $0.01 on Monday, reaching $14.88. 289,310 shares of the company’s stock traded hands, compared to its average volume of 435,603. The company has a market capitalization of $1.03 billion, a P/E ratio of -4.52 and a beta of 0.92. Bicycle Therapeutics plc has a 12-month low of $12.17 and a 12-month high of $28.67. The business’s 50 day moving average price is $19.27 and its two-hundred day moving average price is $21.86.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm’s quarterly revenue was down 50.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.26) EPS. Research analysts predict that Bicycle Therapeutics plc will post -3.05 earnings per share for the current year.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCYC. Assetmark Inc. acquired a new position in shares of Bicycle Therapeutics in the third quarter worth $34,000. GAMMA Investing LLC increased its position in Bicycle Therapeutics by 105.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after purchasing an additional 1,038 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after purchasing an additional 2,918 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after buying an additional 1,782 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter valued at approximately $206,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Wall Street Analysts Forecast Growth

BCYC has been the topic of several recent research reports. B. Riley reduced their price objective on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Stephens began coverage on Bicycle Therapeutics in a report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price target for the company. HC Wainwright decreased their target price on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a research note on Monday, December 16th. Finally, Needham & Company LLC restated a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.